Hypothesis and Theory
Published on 01 May 2013
How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?
in Multiple Sclerosis and Neuroimmunology
Frontiers in Neurology
doi 10.3389/fneur.2013.00010
- 21,289 views
- 25 citations